Tel Aviv - Delayed Quote ILA

Pluri Inc. (PLUR.TA)

1,744.00

+14.00

+(0.81%)

At close: 3:49:43 PM GMT+3

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

Acquisition of approximately 71% stake in Kokomodo Ltd.Acquisition uniquely combines Pluri's mass-scale cell production expertise with Kokomodo Ltd.’s ability to craft real, controlled, climate-resilient cacao using cellular agriculture technology HAIFA, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventu

GlobeNewswire 6 days ago

PLUR
+2.22%
Pluri’s immune cell expansion technologies gain patents

Pluri's total IP estate currently involves more than 250 allowed, granted and pending patents.

Pharmaceutical Technology 23 days ago

PLUR
+2.22%
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel

Latest granted patents reinforce Pluri’s position as a leader in Mucosal-Associated Invariant T (“MAIT”) cell-based cell therapies for solid cancersPluri’s MAIT platform enables commercial scale production of powerful immune cells as a potential first-in-class, ready to use, “off-the-shelf” therapy for cancer patientsPluri’s MAIT platform addresses the global immune cell engineering market, projected to reach approximately $11.7 billion by 2030, and the global cancer immunotherapy market, calcul

GlobeNewswire 24 days ago

PLUR
+2.22%
Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness

Strategic initiative to address Ukraine’s urgent need for radiation countermeasures Hemafund's infrastructure ensures secure storage and rapid deployment of emergency treatments Collaboration may potentially generate over $100 million in value for both parties HAIFA, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative net

GlobeNewswire last month

PLUR
+2.22%
Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution

Food Industry Leader Teams With Ever After Foods to Accelerate Cultivated Meat Market DevelopmentKEMPTTHAL, Switzerland and HAIFA, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Foodtech innovator Ever After Foods (EAF) and global food leader Bühler today announced an expansive cultivated meat collaboration to help food producers around the globe produce cultivated meat efficiently at mass scale. Bühler and Ever After Foods will work together to bring a commercial-scale cultivated meat production sys

GlobeNewswire 2 months ago

PLUR
+2.22%
Pluri: Fiscal Q2 Earnings Snapshot

HAIFA, Israel (AP) — Pluri Inc. PLUR) on Tuesday reported a loss of $3 million in its fiscal second quarter. On a per-share basis, the Haifa, Israel-based company said it had a loss of 53 cents.

Associated Press Finance 2 months ago

PLUR
+2.22%
Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million

New investment follows recent private placement of $6.5 million with global investor and entrepreneur, Mr. Alejandro WeinsteinFunds are intended to support Pluri’s growth and execution strategy as a global leader in cell-based technology HAIFA, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE:PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today a

GlobeNewswire 2 months ago

PLUR
+2.22%
Pluri gets $6.5M investment from Alejandro Weinstein, enters cacao market

Pluri (PLUR) announced a $6.5M strategic private investment led by global investor Alejandro Weinstein, who will join Pluri’s board of directors. Concurrently, Pluri is acquiring a 71% stake in Kokomodo, an AgTech company specializing in cultivated cacao production, for $4.5M payable in the company’s common shares. The investment and the Kokomodo transaction position Pluri to expand its leadership in sustainable food technologies and strengthen its strategic growth and operational capabilities.

TipRanks 3 months ago

PLUR
+2.22%
Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition

Private placement of $6.5 million with a global investor and entrepreneur, Mr. Alejandro Weinstein, who will join Pluri’s Board of DirectorsPluri to purchase approximately 71% of Kokomodo Ltd.’s shares, a leading AgTech company focused on the production of cacao, subject to shareholder approval HAIFA, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE:PLUR) ("Pluri" or the “Company"), a leading biotechnology company leveraging its proprietary platform for cell-based soluti

GlobeNewswire 3 months ago

PLUR
+2.22%
$Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease$

Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

HAIFA, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), an innovator in the development of leading cell-based technologies for various indications, congratulates Mesoblast Ltd. (“Mesoblast”) and its Chief Executive Officer, Silviu Itescu, on the U.S. Food and Drug Administration (the “FDA”) approval of the first MSC-based therapy for steroid-refractory acute graft-versus-host disease (“SR-aGVHD”). This landmark achievement marks a pivot

GlobeNewswire 4 months ago

PLUR
+2.22%
Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025

PluriCDMO™, the Company’s contract development and manufacturing organization, recognized as a leading manufacturing collaborator offering scalability and mass scale production to a growing number of innovative life science companiesHAIFA, Israel, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE:PLUR) ("Pluri" or the “Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announ

GlobeNewswire 4 months ago

PLUR
+2.22%
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit Virtual Conference presentations are now available for on-demand viewing. Participants and those ...

ACCESS Newswire 4 months ago

LMFA

CPSH

PLUR
+2.22%
Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns

HAIFA, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced that it is assessing its readiness to initiate mass production of PLX-R18, a novel potential treatment for hematopoietic complications of the acute radiation syndrome (H-ARS) following exposure to nuclear radiation, in response to heigh

GlobeNewswire 5 months ago

PLUR
+2.22%
Pluri First Quarter 2025 Earnings: US$1.08 loss per share (vs US$0.96 loss in 1Q 2024)

Pluri ( NASDAQ:PLUR ) First Quarter 2025 Results Key Financial Results Net loss: US$5.88m (loss widened by 19% from 1Q...

Simply Wall St. 5 months ago

PLUR
+2.22%
Pluri: Fiscal Q1 Earnings Snapshot

HAIFA, Israel (AP) — Pluri Inc. PLUR) on Tuesday reported a loss of $5.9 million in its fiscal first quarter. On a per-share basis, the Haifa, Israel-based company said it had a loss of $1.08.

Associated Press Finance 5 months ago

PLUR
+2.22%
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ: PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables

PR Newswire 5 months ago

BCLI

PLUR
+2.22%
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority

The Israel Innovation Authority will fund Pluri and BIRAD's collaboration to advance MAIT Cell Therapy, led by Professor Cyrille Cohen, Head of the laboratory of tumor immunology and immunotherapy at Bar-Ilan UniversityMAIT cells hold immense potential for immunotherapy and the treatment of solid tumors compared to conventional T-cells, but their expansion has been a challenge until Pluri announced its proprietary MAIT immunotherapy platform in May 2024Global cancer immunotherapy market is expec

GlobeNewswire 6 months ago

PLUR
+2.22%
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Investor Summit Group, an independent organization focused on creating networking opportunities for the MicroCap and SmallCap community, has announced that presentations from the August 20 Microcap ...

ACCESS Newswire 7 months ago

VCIG

SPGC

GNS
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates

PluriCDMO™, the Company’s contract development and manufacturing organization, recognized as a leading manufacturing partner offering scalability and mass scale production to a growing number of innovative life science companiesHAIFA, Israel, July 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global wellbeing and sustainability, today announced it has signed a tech tra

GlobeNewswire 9 months ago

PLUR
+2.22%

KMSTF
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply

Collaboration aims to develop innovative production methods to increase global availability of vegetables, shorten supply chains and promote sustainable agricultureHAIFA, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), which transforms cells into solutions that promote global wellbeing and sustainability, has announced a strategic proof of concept (“POC”) agreement with a leading international agriculture co

GlobeNewswire 9 months ago

PLUR
+2.22%

Performance Overview

Return	PLUR.TA	S&P 500 (^GSPC)
YTD	+11.37%	-3.31%
1-Year	-19.89%	+10.90%
3-Year	-59.08%	+32.24%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pluri Inc. (PLUR.TA)

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

Pluri’s immune cell expansion technologies gain patents

Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel

Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness

Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution

Pluri: Fiscal Q2 Earnings Snapshot

Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million

Pluri gets $6.5M investment from Alejandro Weinstein, enters cacao market

Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition

Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025

Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns

Pluri First Quarter 2025 Earnings: US$1.08 loss per share (vs US$0.96 loss in 1Q 2024)

Pluri: Fiscal Q1 Earnings Snapshot

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates

Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply

Performance Overview